Zahid Chohan, MD
Vascular Surgery · Olean, NYNPI 1275559767
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $72,200 of the $77,453 with a category attached, or 93.2%. Livanova USA, Inc. accounts for 98.9% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $56,210 and has fallen 99.2% since, to $451 in 2024. Among vascular surgery clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 42 payments — averaging $1844.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$77K
- Johnson & Johnson$230
- AstraZeneca$211
- Nevro Corp.$134
- Inari Medical, Inc.$132
- Bard Peripheral Vascular, Inc.$53
- plus $116 from 4 others
What the payments were for
- Speaking & faculty fees$72,20093%
- Travel & lodging$3,9595%
- Food & beverage$1,2942%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 29 | $76,577 |
| Johnson & Johnson | 3 | $230 |
| AstraZeneca | 2 | $211 |
| Nevro Corp. | 1 | $134 |
| Inari Medical, Inc. | 1 | $132 |
| Bard Peripheral Vascular, Inc. | 1 | $53 |
| Organogenesis Inc. | 1 | $39 |
| Medtronic | 2 | $37 |
| Abbott | 1 | $27 |
| Tactile Systems Technology Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$76,159
- Senza$134
- FLOWTRIEVER CATHETER, S$132
- CT THROMBECTOMY SYSTEM KIT$132
- IMFINZI$125
- XARELTO$125
How this compares
$77,453 in reported general payments places this provider in the 90th percentile of 405 vascular surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cilostazol | 94 | $1,240 |
| ClopidogrelClopidogrel Bisulfate | 31 | $231 |
Paid to pharmacies, not to this prescriber.
Other vascular surgery in Olean
- Gary GelbfishNew York$1.9M
- Sundaram RavikumarDobbs Ferry$1.8M
- Antonios GasparisHuntington$1.5M
- Sonya NoorBuffalo$991K
- John LantisNew York$922K
- Brian DerubertisNew York$714K
- James McKinseyNew York$616K
- Peter FariesNew York$494K
- Robert RheeBrooklyn$338K
- Ajit RaoNew York$294K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.